Skip to content

TuHURA Biosciences, Inc. HURA Net Liabilities Assumed In Reverse Recapitalization Not Yet Paid

Net Liabilities Assumed In Reverse Recapitalization Not Yet Paid at other companies

DTC
Datacentrex, Inc. DTCX
-$31.9K
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$2.36M
XCF Global, Inc. Class A Common Stock logo
XCF Global, Inc. Class A Common StockSAFX
-$93.65M
Construction Partners logo
Construction PartnersROAD
$0
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$10K
AMC Robotics Corporation
 logo
AMC Robotics Corporation AMCI
-$8.93K

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept hura:NetLiabilitiesAssumedInReverseRecapitalizationNotYetPaid.

The official record: TuHURA Biosciences, Inc.’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s net liabilities assumed in reverse recapitalization not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s net liabilities assumed in reverse recapitalization not yet paid?
TuHURA Biosciences, Inc. (HURA) reported net liabilities assumed in reverse recapitalization not yet paid of $137.5K in Q4 2024.
What does net liabilities assumed in reverse recapitalization not yet paid mean?
Represents the total net value of liabilities inherited by the company as a result of a reverse recapitalization event. Monitoring this helps investors understand the debt or obligation burden introduced to the balance sheet through the merger process.